The Cleveland Clinic has launched a groundbreaking study to develop a vaccine against Triple Negative Breast Cancer, which affects Black women in larger numbers than other groups.
TNBC is the most aggressive and lethal form of breast cancer. It is twice as likely to occur in Black women.
The trial is aimed at figuring out the highest dose of the vaccine that can be tolerated. The U.S. Food and Drug Administration approved the drug application for the vaccine allowing the hospital campus in Cleveland and Anixa Biosciences to start the study.
“We are hopeful that this research will lead to more advanced trials to determine the effectiveness of the vaccine against this highly aggressive cancer,” Dr. G. Thomas Budd, lead investigator, said in a statement published on the clinic website.
The study is funded by the U.S. Department of Defense and will involve 18-24 patients. It will conclude next September.